Yamazaki Eye Clinic, Tokyo, Japan.
Jpn J Ophthalmol. 2010 Jan;54(1):7-14. doi: 10.1007/s10384-009-0754-8. Epub 2010 Feb 12.
To investigate the effects of switching to SofZia-preserved travoprost (TRV) on superficial punctate keratopathy (SPK) observed in patients using benzalkonium chloride (BAC)-preserved latanoprost (LAT).
Patients with either primary open-angle glaucoma or ocular hypertension treated with LAT for at least 1 month who presented with SPK participated in this prospective, multicenter, open-label uncontrolled study. After the switch from LAT to TRV, patients were monitored at 2 weeks and at 1, 2, and 3 months. The use of concomitantly employed ophthalmic solutions was continued during the observation period. The intensity of SPK in each of five areas defined on the cornea was scored on a standard scale. Repeated measurements were tested with a linear mixed model.
Of the 48 patients enrolled, 45 patients completed the study. After the switch to TRV, the mean SPK score in the whole cornea decreased significantly at every observation point (P < 0.0001 at each point) while intraocular pressure did not change significantly. Throughout the observation period, the SPK score tended to be higher in patients using a larger number of concomitant medications that contained BAC.
Switching to TRV improved SPK observed in a population using LAT, likely because of a decrease in exposure to BAC.
研究从含有苯扎氯铵（BAC）的拉坦前列素（LAT）转换为 SofZia 保存的曲伏前列素（TRV）对使用 LAT 治疗的伴有浅层点状角膜病变（SPK）的患者的影响。
本前瞻性、多中心、开放标签、非对照研究纳入了至少使用 LAT 治疗 1 个月后出现 SPK 的原发性开角型青光眼或高眼压症患者。从 LAT 转换为 TRV 后，患者在 2 周和 1、2、3 个月时进行监测。在观察期间继续使用同时使用的眼部溶液。在角膜上定义的五个区域中的每个区域的 SPK 强度均使用标准量表进行评分。采用线性混合模型对重复测量值进行检验。
在纳入的 48 例患者中，有 45 例完成了研究。从 TRV 转换后，整个角膜的平均 SPK 评分在每个观察点均显著下降（每个点均 P <0.0001），而眼内压无明显变化。在整个观察期间，使用含有 BAC 的更多种同时使用药物的患者的 SPK 评分往往更高。
转换为 TRV 改善了使用 LAT 的患者的 SPK，这可能是由于暴露于 BAC 的减少。
